324 related articles for article (PubMed ID: 16104110)
1. [Clinical implications of new insights into the regulation of bone resorption].
Lems WF; Bijlsma JW
Ned Tijdschr Geneeskd; 2005 Jul; 149(30):1664-7. PubMed ID: 16104110
[TBL] [Abstract][Full Text] [Related]
2. Osteoprotegerin and its ligand: A new paradigm for regulation of osteoclastogenesis and bone resorption.
Aubin JE; Bonnelye E
Medscape Womens Health; 2000 Mar; 5(2):5. PubMed ID: 10792853
[TBL] [Abstract][Full Text] [Related]
3. RANKL-RANK signaling in osteoclastogenesis and bone disease.
Wada T; Nakashima T; Hiroshi N; Penninger JM
Trends Mol Med; 2006 Jan; 12(1):17-25. PubMed ID: 16356770
[TBL] [Abstract][Full Text] [Related]
4. Evidence of a role for RANKL in the development of myeloma bone disease.
De Leenheer E; Mueller GS; Vanderkerken K; Croucher PI
Curr Opin Pharmacol; 2004 Aug; 4(4):340-6. PubMed ID: 15251126
[TBL] [Abstract][Full Text] [Related]
5. Novel aspects on RANK ligand and osteoprotegerin in osteoporosis and vascular disease.
Sattler AM; Schoppet M; Schaefer JR; Hofbauer LC
Calcif Tissue Int; 2004 Jan; 74(1):103-6. PubMed ID: 14523602
[TBL] [Abstract][Full Text] [Related]
6. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases.
Hofbauer LC; Schoppet M
JAMA; 2004 Jul; 292(4):490-5. PubMed ID: 15280347
[TBL] [Abstract][Full Text] [Related]
7. [Osteoclast function is regulated by neighbouring osteoblasts. Osteoprotegerin, RAND and RANK ligand constitute a unique regulatory system for bone resorption with important pathophysiological and therapeutic aspects].
Ueland T; Bollerslev J; Mosekilde L
Ugeskr Laeger; 2002 Jul; 164(27):3526-30. PubMed ID: 12116680
[TBL] [Abstract][Full Text] [Related]
8. Anti-RANKL therapy for inflammatory bone disorders: Mechanisms and potential clinical applications.
Anandarajah AP; Schwarz EM
J Cell Biochem; 2006 Feb; 97(2):226-32. PubMed ID: 16240334
[TBL] [Abstract][Full Text] [Related]
9. Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system.
Tanaka S; Nakamura K; Takahasi N; Suda T
Immunol Rev; 2005 Dec; 208():30-49. PubMed ID: 16313339
[TBL] [Abstract][Full Text] [Related]
10. [Osteoclastogenesis Inhibitory Factor (OCIF) /Osteoprotegerin (OPG) as a new therapeutic agent for osteoporosis].
Mochizuki S; Kiyokawa A; Nagayama Y
Clin Calcium; 2005 Jan; 15(1):35-42. PubMed ID: 15632471
[TBL] [Abstract][Full Text] [Related]
11. New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand (RANKL).
Giuliani N; Colla S; Rizzoli V
Exp Hematol; 2004 Aug; 32(8):685-91. PubMed ID: 15308315
[TBL] [Abstract][Full Text] [Related]
12. Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin.
Collin-Osdoby P
Circ Res; 2004 Nov; 95(11):1046-57. PubMed ID: 15564564
[TBL] [Abstract][Full Text] [Related]
13. RANK ligand and TNF-alpha mediate acid-induced bone calcium efflux in vitro.
Frick KK; LaPlante K; Bushinsky DA
Am J Physiol Renal Physiol; 2005 Nov; 289(5):F1005-11. PubMed ID: 15972386
[TBL] [Abstract][Full Text] [Related]
14. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling.
Theoleyre S; Wittrant Y; Tat SK; Fortun Y; Redini F; Heymann D
Cytokine Growth Factor Rev; 2004 Dec; 15(6):457-75. PubMed ID: 15561602
[TBL] [Abstract][Full Text] [Related]
15. Osteoprotegerin and receptor activator of nuclear factor-kappaB ligand system in the early post-operative period of liver transplantation.
Fábrega E; Orive A; García-Unzueta M; Amado JA; Casafont F; Pons-Romero F
Clin Transplant; 2006; 20(3):383-8. PubMed ID: 16824158
[TBL] [Abstract][Full Text] [Related]
16. The osteoprotegerin/osteoprotegerin ligand family: role in inflammation and bone loss.
Yeung RS
J Rheumatol; 2004 May; 31(5):844-6. PubMed ID: 15124240
[No Abstract] [Full Text] [Related]
17. Statins modulate the levels of osteoprotegerin/receptor activator of NFkappaB ligand mRNA in mouse bone-cell cultures.
Kaji H; Kanatani M; Sugimoto T; Chihara K
Horm Metab Res; 2005 Oct; 37(10):589-92. PubMed ID: 16278780
[TBL] [Abstract][Full Text] [Related]
18. Characterization of osteoprotegerin binding to glycosaminoglycans by surface plasmon resonance: role in the interactions with receptor activator of nuclear factor kappaB ligand (RANKL) and RANK.
Théoleyre S; Kwan Tat S; Vusio P; Blanchard F; Gallagher J; Ricard-Blum S; Fortun Y; Padrines M; Rédini F; Heymann D
Biochem Biophys Res Commun; 2006 Aug; 347(2):460-7. PubMed ID: 16828054
[TBL] [Abstract][Full Text] [Related]
19. Update on the pathogenesis of osteolysis in multiple myeloma patients.
Giuliani N; Colla S; Rizzoli V
Acta Biomed; 2004 Dec; 75(3):143-52. PubMed ID: 15796087
[TBL] [Abstract][Full Text] [Related]
20. Circulating osteoprotegerin and soluble RANKL: do they have a future in clinical practice?
Dovio A; Data V; Angeli A
J Endocrinol Invest; 2005; 28(10 Suppl):14-22. PubMed ID: 16550717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
